Psyence Biomedical (PBM) Receivables - Net (2023 - 2024)
Psyence Biomedical (PBM) posted Receivables - Net of $36639.6 for Q1 2024, down 75.47% on a QoQ basis from $149369.0 in Q1 2023, and down 75.47% year-over-year from $149369.0 in Q2 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Receivables - Net (2023 - 2024) Analysis & Trends
Psyence Biomedical has reported Receivables - Net for 2 years, with the latest figure at $36639.6 in Q1 2024.
- On a quarterly basis, Receivables - Net fell 75.47% year-over-year to $36639.6 in Q1 2024; TTM through Mar 2024 was $36639.6, a 75.47% decrease from a year earlier, with the FY2024 full-year figure at $36639.6, down 75.47% from the prior year.
- Receivables - Net was $36639.6 for Q1 2024 at Psyence Biomedical, down from $149369.0 in the prior quarter.
- The five-year high for Receivables - Net was $149369.0 in Q1 2023, with the low at $36639.6 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn |
| 10 | Psyence Biomedical | 2.63 Mn | 2.63 Mn | - |